A Placebo-controlled, Double-blind, Randomized Trial to Compare the Effect of Different Doses of ALN-PCSSC Given as Single or Multiple Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated LDL-C
Phase of Trial: Phase II
Latest Information Update: 21 Nov 2017
At a glance
- Drugs Inclisiran (Primary)
- Indications Atherosclerosis; Hypercholesterolaemia
- Focus Therapeutic Use
- Acronyms ORION; ORION-1
- Sponsors The Medicines Company
- 15 Nov 2017 Status changed from active, no longer recruiting to completed.
- 28 Aug 2017 According to an Alnylam Pharmaceuticals media release, one year data from the study has been presented in the "Hot Line - Late-Breaking Clinical Trials 2" session at the European Society of Cardiology (ESC) Congress 2017.
- 28 Aug 2017 New 1-year data published in an Alnylam Pharmaceuticals media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History